FDA said Monday it had approved Allergan’s drug for relieving migraine complications after their onset.
The drug, Ubrelvy, is the first oral model of a brand new class of medicine referred to as calcitonin gene-related peptide (CGRP) inhibitors to win the FDA’s permission for treating the neurological illness.
This new class of drugs acts by interfering with CGRP, a protein concerned in causing extreme headaches.
Allergan, which has been driving to solidify its presence in the migraine market, is growing another oral CGRP inhibitor for migraine prevention known as atogepant.
With the brand new drugs, the corporate hopes to increase beyond selling Botox, a purified form of botulinum toxin that further prevents migraine.
Offering medicine for both prevention and treatment of migraine, Allergan will have “the most complete” product line for neurologists and first care physicians who are managing the situation, Chief Industrial Officer Bill Meury said.
Rival products such as Amgen and Novartis’ Aimovig, Eli Lilly and Co’s Emgality and Teva Pharmaceutical Industries’ Ajovy gained permission within months of each other in 2018, signaling a threat to Botox’s position as a therapeutic.
Botox, which is utilized as a cosmetic treatment to relieve wrinkles, has also been facing competitors from new players to the medical aesthetics space, such as Evolus Inc’s Jeuveau.
Ubrelvy’s permission helps Allergan beat competitor Biohaven Pharmaceutical Holding Firm by securing an FDA nod for the primary oral CGRP inhibitor for treating acute migraine.
Allergan is focused on putting Ubrelvy as an alternative for sufferers who’re taking triptans, a mainstay in the treatment of severe migraine.